LEADER 06548nam 2200589Ia 450 001 9910970402003321 005 20251116233342.0 010 $a1-62081-098-0 035 $a(CKB)2560000000103724 035 $a(EBL)3022467 035 $a(SSID)ssj0000915997 035 $a(PQKBManifestationID)11490804 035 $a(PQKBTitleCode)TC0000915997 035 $a(PQKBWorkID)10875558 035 $a(PQKB)11731154 035 $a(MiAaPQ)EBC3022467 035 $a(Au-PeEL)EBL3022467 035 $a(CaPaEBR)ebr10719465 035 $a(OCoLC)847526872 035 $a(BIP)41214101 035 $a(EXLCZ)992560000000103724 100 $a20120125d2012 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aLupus $esymptoms, treatment and potential complications /$fThiago Devesa Marquez and Davi Urgeiro Neto, editors 205 $a1st ed. 210 $aHappauge, NY $cNova Science Publishers$dc2012 215 $a1 online resource (221 p.) 300 $aDescription based upon print version of record. 311 08$a1-62081-078-6 320 $aIncludes bibliographical references and index. 327 $aIntro -- LUPUS: SYMPTOMS, TREATMENT AND POTENTIAL COMPLICATIONS -- LUPUS: SYMPTOMS, TREATMENT AND POTENTIAL COMPLICATIONS -- Library of Congress Cataloging-in-Publication Data -- Contents -- Preface -- Chapter I: Lupus Erythematosus: A Comprehensive Review -- Abstract -- Abbreviations -- Defining Lupus -- Lupus Incidence and Prevalence -- Causes of Lupus -- Diagnosing Lupus -- Autoantibodies in Lupus -- Lupus Blood Tests -- Urine Testing -- Other Tests -- Pregnancy and Contraception for Women with Lupus -- Current Research in Lupus -- Genetics in Lupus -- Biomarkers -- The Disease Process -- Lupus and the Skin, Hair and Mucosae -- Lupus and the Sun -- Lupus and the Musculoskeletal System -- Podiatric Care in Lupus -- Lupus and the Mucosae -- Mixed Connective Tissue Disease, or Overlap Syndrome -- Differential Diagnoses of Lupus -- Coping with Lupus among Family and Friends -- Treatment -- NSAIDs -- Antimalarials -- Corticosteroids -- Immunosuppressives -- BLyS-Specific Inhibitors -- Other Lupus Therapies -- Alternative and Complementary Therapies -- References -- Chapter II: Autoantibody-Producing B Cellsand B Cell Therapy in Systemic Lupus Erythematosus - Possible New Targets of Novel Subsets of RP105-NegativeB Cells -- Abstract -- Introduction -- Section 1. B Cell Biology in SLE -- Section 2. Therapies of Targeting B Cells in SLE -- Conclusion -- Reference -- Chapter III: Neuropsychiatric Manifestations in Systemic Lupus Erythematosus -- Abstract -- Introduction -- Classification Criteria -- NPSLE Epidemiology -- Clinical Relevance -- Risk Factors for NPSLE -- Pathophysiology -- Diagnosis -- Clinical and Laboratory Investigation -- Therapeutic Strategies in NPSLE -- Conclusion -- Acknowledgments -- References -- Chapter IV: Treatment in Systemic Lupus Erythematosus -- Abstract -- Introduction -- Conventional Therapies -- B-Cell Targeting. 327 $aT-Cell Targeting and Co-Stimulatory Blockade -- Anticytokines Therapy -- Complement Inhibition -- Conclusion -- Acknowledgments -- References -- Chapter V: Hematologic Manifestations of Systemic Lupus Erythematosus -- Anemia -- Leukopenia -- Lymphopenia -- Neutropenia -- Thrombocytopenia -- Bone Marrow as a Target Organ in SLE -- Hematological Manifestations, SLE Subsets and Prognosis -- References -- Chapter VI: Interleukin-21 in Systemic Lupus Erythematosus: Pathogenic Relevance and Therapeutic Applications -- Abstract -- Introduction: Overview on Systemic Lupus Erythematosus -- Multiple Roles for B Cells in SLE -- IL-21 Is aCritical Regulator of B Cell Responses -- IL-21 and SLE -- Treatment of Spontaneous Lupus Mice Using Agents Able to Block IL-21/IL-21R Signaling -- Conclusion -- References -- Chapter VII: Metabolic Syndrome and Inflammatory Cytokines in Systemic Lupus Erythematosus -- Abstract -- Introduction -- CVD in SLE -- Traditional Risk Factors -- Non-Traditional Risk Factors -- CVD Features and Cytokines Involved on SLE -- Relationship between SLE Treatment in Patients with MetS -- What Is the Best Treatment to MetS in SLE Patients? -- Conclusion and Perspective Future -- Acknowledgments -- References -- Chapter VIII: Pulmonary Hypertensionin Systemic Lupus Erythematosus -- Definition -- Classification -- Pulmonary Manifestations in SLE -- Epidemiology -- Pathogenesis -- Clinical Manifestations -- Diagnostic Methods -- Autoantibodies -- Pregnancy -- Treatment -- Immunosuppressive Therapy -- Sildenafil -- Prostanoids -- Endothelin Receptor Antagonists -- Transplantation -- Prognosis -- Conclusion -- References -- Chapter IX: Dual Roles for Antibodies in Lupus Nephritis -- Abstract -- The Origins of Pathogenic Antibodies in Autoimmunity -- Pathogenic Antibodies in Lupus -- Anti-DsDNA IgM Protects against Lupus Nephritis -- Conclusion. 327 $aReferences -- Chapter X: Treatment of Systemic Lupus Erythematosus with Intravenous Immunoglobulins: Case Studies -- Abstract -- Introduction -- Case Study 1 -- Case Study 2 -- Discussion -- Conclusion -- References -- Chapter XI: APRV (Airway Pressure-Release Ventilation) as Supportive Management for Diffuse Alveolar Hemorrhage with Systemic Lupus Erythematosus -- Abstract -- Introduction -- APRV and DAH -- Cases -- References -- Index. 330 $aLupus is one of many disorders of the immune system known as auto-immune diseases, wherein the immune system attacks parts of the patient's body, leading to inflammation and injury in body tissues. This book presents current research in the study of the symptoms, treatment and potential complications of lupus. Topics include autoantibody-producing B cells and B cell therapy in systemic lupus erythematosus; neuropsychiatric and hematologic manifestations of systemic lupus erythematosus; pulmonary hypertension in systemic lupus erythematosus; dual roles for antibodies in lupus nephritis; and treatment of systemic lupus erythematosus with intravenous immunoglobulins. 606 $aSystemic lupus erythematosus 606 $aAutoimmune diseases 615 0$aSystemic lupus erythematosus. 615 0$aAutoimmune diseases. 676 $a616.7/72 701 $aMarquez$b Thiago Devesa$01867603 701 $aNeto$b Davi Urgeiro$01867604 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910970402003321 996 $aLupus$94475227 997 $aUNINA